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Abstract 
Trastuzumab is an important biological agent in the treatment of HER2-positive breast 
cancer, with effects on response rates, progression-free survival, overall survival and quality 
of life. Although this drug is well tolerated in terms of adverse effects, trastuzumab-
associated myocardiotoxicity has been described to have an incidence of 0.6–4.5% and in 
rare cases, the drug can trigger severe congestive heart failure with progression to death or 
even mimic acute coronary syndrome with complete left bundle branch blockade. In this 
paper is reported a case of trastuzumab-associated myocardiotoxicity manifesting as acute 
coronary syndrome in a 69-year-old female. The patient is currently undergoing a 
conservative clinical treatment that restricts overexertion. 
The majority of clinical studies report trastuzumab-induced cardiotoxicity as a rare event, 
and, when present, characterized by mild to moderate clinical signs, the ease of reversibility 
with pharmacological measures and the temporary discontinuation of the medication. 
Conversely, it is vital for the oncologist/cardiologist to consider the possibility that 
trastuzumab-induced cardiotoxicity may manifest itself as a severe clinical case, mimicking 
acute coronary syndrome, justifying careful risk stratification and adequate cardiac 
monitoring, especially in high-risk patients. 
 
Trastuzumab is an important biological agent in the treatment of HER2-positive 
breast cancer, with effects on response rates, progression-free survival, overall survival 
and quality of life. The drug was approved by the United States Food and Drug 
Administration in 1998 for the treatment of metastatic breast cancer, and in 2006, its 
use was expanded for treatment of adjuvant HER2-positive breast cancer. The  
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Herceptin Adjuvant (HERA), National Surgical Adjuvant Breast and Bowel Project B-31 
(NSABP B-31), North Central Cancer Treatment Group N9831 (NCCTG N9831), Breast 
Cancer International Research Group 006 (BCIRG 006) and Finland Herceptin (FinHER) 
clinical trials showed that adding trastuzumab to standard chemotherapy confers a 
gain of approximately 50% in the reduction of recurrence and of 33% in the reduction 
of risk of death [1–5]. 
Although this drug is well tolerated in terms of adverse effects, trastuzumab-
associated myocardiotoxicity has been described to have an incidence of 0.6–4.5%, 
which is reversible with the discontinuation of the medication [6, 7]. In rare cases, the 
drug can trigger severe congestive heart failure with progression to death or even 
mimic acute coronary syndrome with complete left bundle branch blockade [8]. 
Myocardiotoxicity can be manifested through progressive heart failure (HF) symptoms; 
the risk of severe HF was found to be 0.6% in the HERA study and 4.1% in the NSABP 
B-31 study [1, 2]. 
Here, we report a case of trastuzumab-associated myocardiotoxicity manifesting as 
acute coronary syndrome (ACS) in a 69-year-old female. The patient had a history of 
well-controlled systemic arterial hypertension and diabetes mellitus and a diagnosis of 
locally advanced invasive ductal carcinoma of the right breast (T4bN3M0), with 
positive hormone and HER2 receptors. Neoadjuvant chemotherapy was performed 
with six cycles of docetaxel and epirubicin (accumulated dose of epirubicin of 337 
mg/m2), with a partial response according to RECIST. The patient was subjected to a 
mastectomy with axillary dissection, followed by radiotherapy of the plastron and 
supraclavicular fossa. Radiotherapy was followed with hormone therapy with letrozole 
at 2.5 mg/day, combined with trastuzumab at an initial dose of 8 mg/kg (634 mg) and a 
maintenance dose of 6 mg/kg (468 mg). Eleven trastuzumab infusions were performed, 
with the last being conducted 15 days before hospitalization. The patient was admitted 
with complaints of progressive dyspnea for 1 week, with profound deterioration in the 
previous hour. At the physical exam, the patient had shortness of breath and labored 
breathing, with a respiratory rate of 24, bilateral crackles up to the lung apices, oxygen 
saturation of 72% in room air, heart rate of 126 and blood pressure of 170/110 mm Hg. 
After diagnosing acute pulmonary edema, noninvasive mechanical ventilation and 
intravenous nitroglycerin were administered. An electrocardiogram (ECG) was 
performed, showing an advanced left bundle branch block (LBBB) that was nonexistent 
in a previous examination (fig. 1). Myocardial necrosis markers were high (CK-MB: 52 
U/l; troponin I: 1.66 µg/l), as was NT-proBNP (3,914 pg/ml). Although the patient had 
a normal examination dated 2 months earlier, her echocardiogram (echo) showed 
markedly reduced left ventricular systolic performance (LVEF: 15%) with diffuse 
hypokinesia and apical thrombus (table 1). Measures for ACS were initiated (aspirin, 
clopidogrel and enoxaparin), and coronary angiography was performed, which 
revealed coronary arteries without signs of obstruction. ACS evolved with the 
disappearance of LBBB on the ECG and the counteraction of clinical symptoms with 
diuretics, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers. 
The clinical and laboratory abnormalities observed were attributed to trastuzumab-
related cardiotoxicity (fig. 2). The patient was discharged with medications for HF in 
combination with oral anticoagulants. At the 30-day follow-up, the patient underwent a 
new echo, showing 25% LVEF associated with significant improvement of dyspnea 
symptoms (fig. 3). Trastuzumab treatment was discontinued and permanently  
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contraindicated. The patient is currently undergoing a conservative clinical treatment 
that restricts overexertion. Trastuzumab is a humanized monoclonal antibody that 
selectively binds to the extracellular domain of the HER2 receptor, a product of the 
gene ERBB2. Its mechanism of action is not completely understood; however, it is 
known that immune responses are involved as well as inhibition of HER2 cleavage, 
inhibition of PI3K and angiogenesis and possible stabilization of cells in the G1 phase of 
the cell cycle [9, 10]. In metastatic disease, trastuzumab provides significant clinical 
benefit, with an increase of 8.5 months in overall survival when combined with 
docetaxel chemotherapy compared to chemotherapy treatment alone [11, 10]. The use 
of trastuzumab in adjuvant treatment reduces the risk of recurrence in approximately 
50% and the mortality rate by approximately 30% of patients [10, 12, 13]. In the 
neoadjuvant setting, the addition of trastuzumab has provided a complete pathological 
response rate of 66.7%, which is significantly higher than the 25% found with 
chemotherapy treatment alone [10, 14]. 
Trastuzumab has been associated with the development of cardiomyopathy, most 
often manifesting with asymptomatic reduction of LVEF and less frequently with the 
presence of clinical signs of HF and arrhythmias. This association includes the 
possibility of cardiac intramural thrombus formation and acute myocardial infarction 
[15–17]. 
The pathophysiology of trastuzumab-related myocardial dysfunction has not been 
well defined, but the following mechanisms have been proposed: drug–drug 
interaction; immune-mediated destruction of cardiomyocytes; defective HER2 signaling 
and signaling for the opening of calcium channels, which are important for the 
maintenance of cardiac contractility; indirect consequences of extracardiac effects of 
trastuzumab and reduction of HER2-mediated cardiomyocyte survival through the 
hypoexpression of HER2 [17]. Cardiac dysfunction induced by trastuzumab appears to 
be primarily due to the inhibition of HER2 signaling in cardiomyocytes, which is 
associated with changes in the expression of BCL-X proteins, ATP depletion and 
consequent contractile dysfunction but without causing changes in cellular structure 
[10, 18]. This phenomenon is a cardiac dysfunction that has no correlation with lesions 
in myocardial cells, with only functional and without morphological effects. 
The inhibition of HER2-mediated pathways caused by trastuzumab prevents the 
response of cardiomyocytes to cardiac overload factors, interfering with gp130 
cytokine and neuregulin signaling, altering the maintenance mechanisms of myocardial 
viability and allowing the onset of cardiac dysfunction [10, 19]. HER2 expression is 
important for embryonic cardiac development and cardioprotection, modulating the 
cardiac response to stress. Mutation of the HER2 gene in animal models leads to early 
death by dilated cardiomyopathy and greater susceptibility to cellular death when 
exposed to anthracyclines. Reduced expression of HER2 may lead to dilated 
cardiomyopathy similar to dilated cardiomyopathy in humans [10, 20]. Through the 
activation of HER2 and ErbB4, neuregulin promotes the hypertrophy of adult 
cardiomyocytes and the proliferation of embryonic cardiomyocytes, protecting them 
from apoptosis [16]. In animal models, neuregulin treatment improves cardiac 
performance and increases survival in animals with cardiomyopathy induced by heart 
attack, drugs or myocarditis, suggesting the possibility of using this substance as a 
treatment for dilated cardiomyopathy [10].  
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HF occurs in 1–4% of patients treated with trastuzumab. In approximately 10% of 
patients, there is a reduction in cardiac function that is reversible in the majority of 
cases. HF has been described both from the use of trastuzumab alone (4%) and in 
combination (27%) with other antineoplastic agents, such as anthracyclines and 
cyclophosphamide. The risk of cardiac dysfunction associated with the use of 
trastuzumab in this circumstance is justified by the 25% gain in overall survival, but it 
must be emphasized that combining these therapies increases the risk of cardiac 
dysfunction in up to 19% of patients when associated with regimens that include 
doxorubicin and cyclophosphamide [2, 3]. In 2005, the Cardiac Review and Evaluation 
Committee (CREC) standardized the criteria for diagnosing cardiac events/dysfunction 
and categorized the events in accordance with the New York Heart Association 
standards. The CREC criteria for diagnosing cardiac dysfunction are cardiomyopathy 
characterized by a decrease in LVEF with global or more severe dysfunction in the 
septum; severe congestive heart failure; associated signs of HF, including gallop, 
tachycardia or both; a decrease of at least 5% and up to 50% in LVEF, followed by signs 
and symptoms of CHF or a decrease of at least 10% and up to 55% without signs of 
symptoms [2, 3]. Data from the NSABP B-31 study, reevaluated according to these 
criteria, showed that among the 31 patients who were given trastuzumab and had 
developed a major cardiac event, 28 developed this cardiac event during trastuzumab 
therapy, and only 3 had subsequent cardiac events after completing the 1-year therapy. 
Of these 31 patients who had a CHF diagnosis, 27 remained under observation for at 
least 6 months after the diagnosis, and 26 of them remained asymptomatic during this 
period. Of these 26 patients, 18 (67%) continued to receive medication for HF. Finally, 
24 of the 27 patients who had remained under observation had LVEF measured over 
the 6-month period following HF diagnosis, and 17 of the 24 patients maintained LVEF 
below baseline (25 to 69%) [2, 3]. 
Analysis of the cumulative risk of cardiotoxicity in the NSABP B-31 and NCCTG 
N9831 studies was impaired due to the short follow-up time and cardiac monitoring, in 
the protocol-specific definition of heart failure, in data collection and in the data review 
process. After analyzing these studies using the CREC criteria, it was found that cardiac 
events occurred in 2% of the patients given trastuzumab and in 0.45% of patients who 
only received chemotherapy after a median follow-up of 2 and 1.9 years, respectively. 
Based on data from the NSABP B-31 study, 1 out of every 30 women treated with 
trastuzumab will develop a cardiac event, defined as cardiac death or severe HF in 3 
years. Furthermore, one in every five women treated with trastuzumab will develop 
some form of cardiac dysfunction that requires the discontinuation of treatment [1, 3]. 
In the BCIRG 006 study, the LVEF of 17.3% of the 1,040 patients treated with the 
adriamycin, cyclophosphamide, taxol, herceptin (ACTH) regimen (table 1) sustained a 
drop of over 10% from baseline after treatment with trastuzumab. In addition to HF, 
cardiac events were also identified in the form of myocardial ischemia and arrhythmias. 
The overall rate of clinically significant cardiac events (grade 3/4) was 0.95% for ACT 
and 2.3% for ACTH (p = 0.016), showing increased toxicity with the combination that 
included trastuzumab [4]. 
The CREC analyzed the risk factors in a univariate analysis for the development of a 
cardiac event. The analysis included the use of trastuzumab (4.38-fold increased risk), 
age over 50 years (2.84-fold increased risk) and low LVEF at the start of the paclitaxel 
regimen and at the end of the doxorubicin regimen (p = 0.0106). The risk increased  
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from 0.6% for patients without any risk factors to 5.2% for the trastuzumab group, 
whereas for chemotherapy-only treatment, this risk increased from 0.3 to 2.4% [1, 2]. 
In 2007, as a result of the update of the NSABP B-31 study results, a predictive model 
was proposed for the occurrence of cardiac events in patients previously treated with 
anthracycline and trastuzumab, analyzing criteria such as age, LVEF and the presence 
of systemic arterial hypertension (SAH) during trastuzumab treatment [21]. 
{[7.4 + (0.03 × age) – (0.1 × LVEF) + 0.68 se SAH] × 100}/4.82 
Previous or concomitant use of anthracycline (cumulative dose of 400 mg/m2) or 
taxanes, chest wall irradiation, antihypertensive therapy and preexisting cardiac 
dysfunction are additional risk factors for cardiac dysfunction, in addition to obesity 
and age over 60 years. 
Conversely, valvular heart disease and type 2 diabetes mellitus do not significantly 
increase the risk of cardiotoxicity using multivariate analysis [3, 6, 7]. The patient from 
our case report had the risk factors of age over 60 years, hypertension, diabetes and 
grade I obesity, and she had undergone radiotherapy and was not given ACE inhibitors 
to control SAH. The patient had also received a cumulative dose of epirubicin of 337 
mg/m2. Therefore, she was at high risk for developing cardiotoxicity resulting in 
cardiomyopathy. 
Although patients with SAH and inadequate blood pressure control were excluded 
from the trastuzumab trial, patients with controlled SAH were given randomized 
treatment regimens. In NSABP B-31, approximately 20% of patients randomized for 
trastuzumab use were given some type of antihypertensive medication concomitantly. 
It is possible that many of these patients were already using ACE inhibitors and/or 
beta-blockers, which both favorably alter the natural course of left ventricle 
dysfunction. In this context, it is possible that the use of these agents favorably 
influenced the low cumulative incidence of cardiotoxicity observed [2, 22]. 
In the management of cardiotoxicity by trastuzumab, it remains unknown whether 
there are any benefits to introducing ACE inhibitors, which have been shown to be 
effective in slowing the progression of left ventricle cardiac dysfunction in several 
different clinical scenarios such as anthracycline-induced cardiomyopathy. In this 
sense, it is likely that in high-risk patients, prophylactic strategies based on ACE 
inhibitors are able to prevent certain cardiotoxicity events related to medications [22]. 
The factors identified in these analyses can help in the risk stratification of 
individual patients to develop a cardiac event. Nevertheless, it is still not possible to 
identify with any certainty the population of patients who will experience a cardiac 
event related to trastuzumab treatment or to identify an exact value for LVEF that 
characterizes an increased risk [1, 3]. Conversely, there are specific recommendations 
for monitoring cardiac function during trastuzumab treatment and guidelines on 
suspension or maintenance of treatment according to changes in the cardiac ejection 
fraction. Typically, LVEF is the reference standard for cardiac function monitoring, but 
this technique has less sensitivity in addition to being examiner-dependent. New 
monitoring methods such as NT-proBNP and troponin I have been used as validated 
tools and in the early identification of cardiac damage [21–23].  
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Based on the HERA study, which had a 3.6-year follow-up period, assessment of 
cardiotoxicity was proposed. This assessment included cardiac monitoring, a 
questionnaire, a physical exam and an ECG during the first consultation in addition to 
LVEF assessment by echo or scintigraphy of the heart chambers (multigated acquisition 
heart scan) at 3, 6, 12, 18, 24, 30, 36 and 48 months and annually between 5 and 10 
years [1, 23]. 
Currently, real-time 3D transthoracic echo is a viable method to accurately assess 
the changes in the values of LV volume and LVEF and also to serially monitor patients 
receiving chemotherapy with anthracyclines or trastuzumab [23]. 
Among the noninvasive imaging modalities, magnetic resonance imaging is the most 
accurate and reproducible because it can detect subtle changes in LVEF; however, due 
to its high cost, low availability and the need for a trained specialist for its 
interpretation, this technique has not been used to monitor cardiotoxicity in clinical 
studies [23]. In clinical practice, the choice of imaging method is directly related to the 
availability of resources of the healthcare center. 
The majority of clinical studies report trastuzumab-induced cardiotoxicity as a rare 
event, and, when present, characterized by mild to moderate clinical signs, the ease of 
reversibility with pharmacological measures and the temporary discontinuation of the 
medication. Conversely, it is vital for the oncologist/cardiologist to consider the 
possibility that trastuzumab-induced cardiotoxicity may manifest itself as a severe 
clinical case, mimicking ACS, justifying careful risk stratification and adequate cardiac 
monitoring, especially in high-risk patients. 
 
 
 
Table 1. Treatment protocols of clinical studies that used trastuzumab for breast cancer 
                                   
NSABP B-31    NCCTG N9831    HERA    BCIRG 006    FinHER 
                                   
AC every 21 days for 4 
cycles + Pac every 21 
days for 4 cycles 
  AC every 21 days for 4 
cycles + weekly PAC for 12 
cycles 
  4 or more QT cycles + 
observation 
  AC every 21 days for 4 cycles 
+ Doc every 21 days for 4 
cycles 
  Doc every 21 days for 3 
cycles + weekly TZM for 9 
cycles + FEC for 3 cycles 
                                    AC every 21 days for 4 
cycles + Pac every 21 
days for 4 cycles + 
weekly TZM for 1 year 
  AC every 21 days for 4 
cycles >Pac without for 12 
cycles >TZM without for 1 
year 
  4 or more QT cycles + 
TZM every 21 days for 
1 year 
  AC every 21 days for 4 cycles 
+ Doc every 21 days for 4 
cycles + weekly TZM for 12 
weeks + TZM every 21 days 
for 40 weeks for 1 year 
  Doc every 21 days for 3 
cycles + FEC for 3 cycles 
                                        AC every 21 days for 4 
cycles >Pac without for 12 
cycles + TZM without for 1 
year 
  4 or more QT cycles + 
TZM every 21 days for 
2 years 
  Doc + Cap every 21 days for 6 
cycles + weekly TZM for 18 
weeks + every 21 days for 1 
year 
  Vin every 21 days for 3 
cycles + weekly TZM for 9 
cycles + FEC for 3 cycles 
                                                    Vin every 21 days for 3 
cycles + FEC for 3 cycles 
                                   
NSABP = National Surgical Adjuvant Breast and Bowel Project; NCCTG = North Central Cancer Treatment Group; HERA = Herceptin 
Adjuvant trial; AC = doxorubicin (Adriamycin) and cyclophosphamide; BCIRG = Breast Cancer International Research Group; FinHER = 
Finland Herceptin trial; FEC = fluorouracil, epirubicin, cyclophosphamide; Pac = paclitaxel; TZM = trastuzumab; Cap = carboplatin; Doc = 
docetaxel; Vin = vinorelbine. 
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Fig. 1. Chest radiograph with cardiomegaly and pulmonary congestion. ECG with sinus tachycardia, 
advanced LBBB and ST-segment elevation on the anterior wall of the myocardium (July 13, 2010). 
 
 
 
Fig. 2. Chest radiograph showing cardiomegaly without pulmonary congestion. ECG with sinus 
rhythm, HR of approximately 100 bpm and a lesion on the anterior wall (July 16, 2010). 
 
 
 
Fig. 3. Temporal correlation of LVEF. 
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